Alembic Pharmaceuticals Ltd
APLLTDAlembic Pharmaceuticals Ltd
APLLTDPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
33.57 | 4.51 | 1.00% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast from 11 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Investor Presentation
View olderÂPeers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,173.11 | 3,107.17 | 3,137.84 | 3,944.06 | 4,610.69 | 5,480.42 | 5,361.53 | 5,655.36 | 6,256.93 | 6,396.64 | ||||||||||
Raw Materials | 877.07 | 928.05 | 927.62 | 1,084.97 | 1,249.98 | 1,451.27 | 1,489.61 | 1,630.17 | 1,857.92 | 5,355.17 | ||||||||||
Power & Fuel Cost | 58.89 | 64.20 | 70.35 | 88.86 | 102.40 | 118.72 | 120.84 | 151.54 | 173.37 | |||||||||||
Employee Cost | 472.85 | 558.83 | 622.81 | 746.69 | 906.44 | 1,051.17 | 1,133.00 | 1,169.13 | 1,446.29 | |||||||||||
Selling & Administrative Expenses | 507.40 | 791.13 | 700.51 | 961.11 | 913.65 | 1,104.03 | 1,354.87 | 1,474.00 | 1,543.70 | |||||||||||
Operating & Other expenses | 243.09 | 147.67 | 166.42 | 179.47 | 253.92 | 187.65 | 333.31 | 550.33 | 274.96 | |||||||||||
EBITDA | 1,013.81 | 617.29 | 650.13 | 882.96 | 1,184.30 | 1,567.58 | 929.90 | 680.19 | 960.69 | 1,041.47 | ||||||||||
Depreciation/Amortization | 72.21 | 82.97 | 105.46 | 115.23 | 157.32 | 183.48 | 286.78 | 275.43 | 272.67 | 278.48 | ||||||||||
PBIT | 941.60 | 534.32 | 544.67 | 767.73 | 1,026.98 | 1,384.10 | 643.12 | 404.76 | 688.02 | 762.99 | ||||||||||
Interest & Other Items | 5.43 | 5.23 | 3.40 | 18.41 | 27.16 | 16.02 | 17.73 | 50.17 | 56.19 | 58.10 | ||||||||||
PBT | 936.17 | 529.09 | 541.27 | 749.32 | 999.82 | 1,368.08 | 625.39 | 354.59 | 631.83 | 704.89 | ||||||||||
Taxes & Other Items | 216.12 | 125.93 | 128.64 | 164.95 | 171.00 | 221.58 | 104.45 | 12.60 | 16.01 | 58.11 | ||||||||||
Net Income | 720.05 | 403.16 | 412.63 | 584.37 | 828.82 | 1,146.50 | 520.94 | 341.99 | 615.82 | 646.78 | ||||||||||
EPS | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 59.55 | 26.50 | 17.40 | 31.33 | 32.90 | ||||||||||
DPS | 3.50 | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | 10.00 | 8.00 | 11.00 | 11.00 | ||||||||||
Payout ratio | 0.09 | 0.19 | 0.18 | 0.18 | 0.23 | 0.24 | 0.38 | 0.46 | 0.35 | 0.33 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alembic Pharmaceuticals Ltd | 35.26 | 4.51 | 1.00% |
Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
Cipla Ltd | 28.51 | 4.38 | 0.89% |
Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare APLLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Kotak Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.7243% | Percentage of the fund’s portfolio invested in the stock 2.11% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/83 (+28) |
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4740% | Percentage of the fund’s portfolio invested in the stock 1.68% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/62 (+3) |
Axis Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7273% | Percentage of the fund’s portfolio invested in the stock 0.65% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 34/132 (+54) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
APLLTD has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 1.00%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.96 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Dividend/Share
₹11.00
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateAug 17, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹14.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 16, 2020
Alembic Pharmaceuticals has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at active pharmaceutical ingredient (API)-II Facilty at Panelav for its 8 APIs. The inspection was conducted from 16 to 20 September 2024. Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients. The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024. The scrip slipped 1.34% to currently trade at Rs 1,088.95 on the BSE.Powered by Capital Market - Live
Alembic Pharmaceuticals announced that it has received Tentative Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pataday Once Daily Relief Ophthalmic Solution, 0.7%, of Alcon Laboratories, Inc. (Alcon) NDA - 206276. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pataday Once Daily Relief Ophthalmic Solution, of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander. According to IQVIA, Olopatadine Hydrochloride Ophthalmic Solution USP has an estimated market size of $22 million for twelve months ending September 2024. Alembic has a cumulative total of 219 ANDA approvals (192 final approvals and 27 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients. The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024. The scrip rose 0.06% to currently trade at Rs 1,101.05 on the BSE. Powered by Capital Market - Live
The GMP inspection was conducted from 14 November 2024 to 22 November 2024. The USFDA issued Form-483 with 5 observations. The company stated that it would provide a comprehensive response to the USFDA for the observations within the stipulated period. It also committed to maintaining the highest quality standards and compliance at all times. Alembic Pharmaceuticals is in the business of development, manufacturing and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024. The scrip rallied 3.44% to currently trade at Rs 1,077.60 on the BSE. Powered by Capital Market - Live
Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ivabradine Tablets, 5 mg and 7.5 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen). Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US$ 145.3 million for twelve months ending September 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (192 final approvals and 26 tentative approvals) from USFDA.Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD extended-release capsules of Bausch Health US, LLC. The approved strengths for the said drug are 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. Diltiazem Hydrochloride Extended-Release (ER) capsules are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications. It is also indicated for the management of chronic stable angina and angina due to coronary artery spasm. Diltiazem Hydrochloride extended-release capsules have an estimated market size of $105.3 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip fell 1.89% to currently trade at Rs 1019.35 on the BSE. Powered by Capital Market - Live
Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD Extended-Release Capsules, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, of Bausch Health US, LLC. Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications. It is also indicated for the management of chronic stable angina and angina due to coronary artery spasm. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of US$105.3 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA. Powered by Capital Market - Live
Net profit of Alembic Pharmaceuticals rose 12.34% to Rs 153.41 crore in the quarter ended September 2024 as against Rs 136.56 crore during the previous quarter ended September 2023. Sales rose 3.33% to Rs 1647.98 crore in the quarter ended September 2024 as against Rs 1594.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1647.981594.93 3 OPM %14.5213.03 - PBDT238.06202.20 18 PBT167.55134.64 24 NP153.41136.56 12 Powered by Capital Market - Live
The headline equity benchmarks traded with limited losses in early-afternoon trade. The Nifty traded below the 24,750 mark. Metal shares decline after rising for the past trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex, was down 197.25 points or 0.24% to 81,026.95. The Nifty 50 index fell 105.15 points or 0.42% to 24,748.90. In the broader market, the S&P BSE Mid-Cap index fell 0.46% and the S&P BSE Small-Cap index shed 0.99%. The market breadth was weak. On the BSE, 1,254 shares rose and 2,637 shares fell. A total of 154 shares were unchanged. Waree Energies IPO received strong interest from investors. The IPO received bids for 3,16,95,741 shares as against 2,10,79,384 shares on offer. The IPO was subscribed 1.50 times. Economy: India's net direct tax collections jumped by 182.02% over last decade to Rs 19.60 lakh crore in FY24, from 6.95 lakh crore in FY15, following strong growth in personal income tax, the latest time series data from the Income Tax Department showed. Personal income tax collections zoomed up nearly 300% to Rs 10.45 lakh crore, from 2.65 lakh crore in FY15, outpacing corporate tax collections, which rose by 112.85% to Rs 9.11 lakh crore from Rs 4.28 lakh crore in FY15. Derivative: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, advanced 7.09% to 13.96. The Nifty 31 October 2024 futures were trading at 24,760.60, at a premium of 95.70 points as compared with the spot at __ . The Nifty option chain for the 31 October 2024 expiry showed maximum Call OI of 92.8 lakh contracts at the 25,000 strike price. Maximum Put OI of 44.2lakh contracts were seen at 24,000 strike price. Buzzing Index: The Nifty Metal index fell 1.40% to 9,617.75. The index advanced 1.57% in the past trading session. Jindal Stainless Ltd (down 5.84%), APL Apollo Tubes Ltd (down 2.42%), NMDC Ltd (down 2.14%), Adani Enterprises Ltd (down 2.1%) and Hindustan Copper Ltd (down 2.04%), Steel Authority of India Ltd (down 1.77%), Hindalco Industries Ltd (down 1.55%), National Aluminium Company Ltd (down 1.49%), Vedanta Ltd (down 0.93%) and JSW Steel Ltd (down 0.9%) declined. Stock in Spotlight: Alembic Pharmaceuticals rose 0.21%. The company has announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg.Powered by Capital Market - Live
Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.67%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.8% to 1.66%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 1.05%, vs industry avg of 15.27%